About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho
transgene insertion 320-1, Gary W Hoyle
MGI:4437863
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cx1
Cyp2g1tm1(rtTA)Lane/Cyp2g1+
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0
involves: 129 * C57BL/6 * SJL MGI:4437872
tg2
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0 involves: C57BL/6 * SJL MGI:4437866


Genotype
MGI:4437872
cx1
Allelic
Composition
Cyp2g1tm1(rtTA)Lane/Cyp2g1+
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0
Genetic
Background
involves: 129 * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cyp2g1tm1(rtTA)Lane mutation (0 available); any Cyp2g1 mutation (30 available)
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment
• the epithelium consists primarily of apical sustentacular cells and basal progenitors at 42 days after doxycycline treatment
• by 14 days after doxycycline withdrawal, the ORNs are extensively regenerated and there is nearly normal axon bundle morphology
• at 28 days after doxycycline withdrawal, the ORN layer is indistinguishable from untreated mice
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment
• inflammatory infiltrate and indistinct axon bundles in the subepithelium at approximately day 21
• dense infiltration of inflammatory cells and an absence of discernable axon bundles in the subepithelium at 42 days after doxycycline treatment
• numerous macrophages in the subepithelium by anti-CD68 immunostaining at 42 days after doxycycline treatment

nervous system
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment

taste/olfaction
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment
• the epithelium consists primarily of apical sustentacular cells and basal progenitors at 42 days after doxycycline treatment
• by 14 days after doxycycline withdrawal, the ORNs are extensively regenerated and there is nearly normal axon bundle morphology
• at 28 days after doxycycline withdrawal, the ORN layer is indistinguishable from untreated mice
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment
• absent odorant-induced electroolfactogram (EOG) amplitudes after 42 days on doxycycline
• the EOG amplitudes return to normal at 14 days after doxycycline withdrawal
• reduced (60%) odorant-induced electroolfactogram (EOG) amplitudes after 14 days on doxycycline

cellular
• no increase in proliferation shown by BrdU staining when the olfactory receptor neurons depleted after doxycycline treatment

immune system
• numerous macrophages in the olfactory subepithelium by anti-CD68 immunostaining at 42 days after doxycycline treatment
• inflammatory infiltrate and indistinct axon bundles in the subepithelium at approximately day 21
• dense infiltration of inflammatory cells and an absence of discernable axon bundles in the subepithelium at 42 days after doxycycline treatment
• numerous macrophages in the subepithelium by anti-CD68 immunostaining at 42 days after doxycycline treatment

hematopoietic system
• numerous macrophages in the olfactory subepithelium by anti-CD68 immunostaining at 42 days after doxycycline treatment

craniofacial
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment
• the epithelium consists primarily of apical sustentacular cells and basal progenitors at 42 days after doxycycline treatment
• by 14 days after doxycycline withdrawal, the ORNs are extensively regenerated and there is nearly normal axon bundle morphology
• at 28 days after doxycycline withdrawal, the ORN layer is indistinguishable from untreated mice
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment

growth/size/body
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment
• the epithelium consists primarily of apical sustentacular cells and basal progenitors at 42 days after doxycycline treatment
• by 14 days after doxycycline withdrawal, the ORNs are extensively regenerated and there is nearly normal axon bundle morphology
• at 28 days after doxycycline withdrawal, the ORN layer is indistinguishable from untreated mice
• reduced olfactory receptor neurons (ORNs) layer thickness beginning at 28 days after doxycycline treatment
• markedly abnormal reduction of the ORN layer at 35 days after doxycycline treatment
• rapid and essentially complete loss of neuronal cells and their corresponding axons at 42 days after doxycycline treatment

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
sinusitis DOID:0050127 J:157842




Genotype
MGI:4437866
tg2
Allelic
Composition
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0
Genetic
Background
involves: C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• lymphocytes in the lung in doxycycline-treated transgenic mice
• clustered inflammatory cells within lymphocytic nodules, within the parenchyma, and adjacent to the pleural surface
• varying degrees of inflammation in untreated transgenic mice, but overall much less pronounced than in doxycycline-treated transgenic mice
• enlarged airspace throughout the lung in transgenic mice treated with doxycycline
• tend to be more pronounced adjacent to lymphoid aggregates
• significant increases in linear intercept in transgenic mice treated with doxycycline for 1-9 months
• significant airspace enlargement at 11-12 months of age in untreated transgenic mice
• some fibrotic lesions in transgenic mouse treated with doxycycline for 6 months
• most commonly adjacent to airways

immune system
• modest increases in the number of neutrophils recovered in lavage fluid (6% of total cells) in doxycycline-treated transgenic mice
• modest increases in the number of lymphocytes recovered in lavage fluid (2% of total cells) in doxycycline-treated transgenic mice
• dendritic cells on the periphery of lymphoid nodules as shown by CD11c immunostaining in doxycycline-treated transgenic mice
• large numbers of B lymphocytes within lymphoid nodules in transgenic mice administered doxycycline for 1-2 months as shown by B220 immunostaining
• T cell-rich zones in some lymphoid nodules as shown by CD3 immunostaining in doxycycline-treated transgenic mice
• increased CD8-positive cells within the lung parenchyma in the transgenic mice administered doxycycline for 1-2 months
• CD4-positive cells in some nodules but no CD8-positive cells in doxycycline-treated transgenic mice
• lymphocytic nodules and enlarged airspaces in the lung of transgenic mice treated with doxycycline for 1 month
• significantly higher number of lymphocytic nodules in doxycycline treated transgenic mice than in untreated transgenic mice
• small to medium sized lymphocytic nodule but normal airspaces in some untreated transgenic mouse of same age
• no inflammatory nodules observed in nontransgenic mice
• lymphocytes in the lung in doxycycline-treated transgenic mice
• clustered inflammatory cells within lymphocytic nodules, within the parenchyma, and adjacent to the pleural surface
• varying degrees of inflammation in untreated transgenic mice, but overall much less pronounced than in doxycycline-treated transgenic mice

hematopoietic system
• modest increases in the number of neutrophils recovered in lavage fluid (6% of total cells) in doxycycline-treated transgenic mice
• modest increases in the number of lymphocytes recovered in lavage fluid (2% of total cells) in doxycycline-treated transgenic mice
• dendritic cells on the periphery of lymphoid nodules as shown by CD11c immunostaining in doxycycline-treated transgenic mice
• large numbers of B lymphocytes within lymphoid nodules in transgenic mice administered doxycycline for 1-2 months as shown by B220 immunostaining
• T cell-rich zones in some lymphoid nodules as shown by CD3 immunostaining in doxycycline-treated transgenic mice
• increased CD8-positive cells within the lung parenchyma in the transgenic mice administered doxycycline for 1-2 months
• CD4-positive cells in some nodules but no CD8-positive cells in doxycycline-treated transgenic mice





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/19/2024
MGI 6.24
The Jackson Laboratory